Are Psychedelics Legal? Psilocybin Laws, Decriminalization, and Medical Access

Interest in the use of psychedelic drugs for treating conditions such as depressive disorders, substance use disorders, post-traumatic stress disorder, and other conditions has greatly increased in recent years. Despite this momentum, no psychedelic drug has been approved in the United States. The legal landscape for psychedelics law remains a patchwork of state laws and federal regulations.

If you need help understanding the legal framework governing psychedelic use in your state or are facing a criminal drug violation, consult a lawyer with experience in drug and alcohol law.

What Are Psychedelic Drugs?

Psychedelic drugs, also known as hallucinogens, are substances that can significantly alter perception, mood, social relatedness, and cognitive processes. These substances affect consciousness without inducing delirium.

Commonly discussed substances under the broad terms of psychedelics include:

• Psilocybin (magic mushrooms) is produced naturally by psilocybin mushrooms
• Entactogens or empathogens such as MDMA
• Lysergic acid diethylamide (LSD)
• Peyote
• Ketamine
• DMT (dimethyltryptamine) and ayahuasca

These substances are known for their striking subjective effects, including visual and perceptual changes, hallucinations, enhanced feelings of connectedness, and deep feelings of emotional and spiritual significance. These subjective effects are influenced by the mindset and physical environment where the psychedelic medicine is used.

Despite their potential, all psychedelic drugs remain illegal, classified as Schedule I substances alongside drugs such as heroin. However, states including Oregon and Colorado have legalized psilocybin psychedelic therapy, signaling a shift in public perception and policy.

The therapeutic potential of psychedelics has garnered significant attention, with substances like psilocin, mescaline, and others being studied for their ability to treat conditions such as depression, PTSD, and substance use disorders. Often grouped under the umbrella of entheogenic compounds, these drugs are at the forefront of groundbreaking mental health research.

Medical and Therapeutic Interest in Psychedelics

While hallucinogens like psilocybin and LSD are often associated with recreational use, they are now being studied for their potential therapeutic benefits. Over the past couple of decades, numerous studies have explored these breakthrough therapies for their effects on various mood, anxiety, substance use disorders, and post-traumatic stress disorders.

Medical research seeks to determine how psychedelics can treat a variety of conditions. Preliminary studies suggest that psychedelics enhance neuroplasticity and may promote learning and cognitive flexibility.

In 2023, the U.S. Food & Drug Administration (FDA) issued draft guidance on clinical trials with psychedelic drugs, and clinical trials are also investigating the therapeutic benefits of psychedelics for additional medical purposes, treating common pain disorders such as migraines, fibromyalgia, and Irritable bowel syndrome.

How Psychedelic-Assisted Therapy Works

Psychedelic drugs have long been used as natural medicine for healing practices and in spiritual practices. Some of the most notable subjective effects of psychedelics are visual perceptual changes, enhanced feelings of connectedness, and deep feelings of emotional and spiritual significance.

In modern psychedelic-assisted therapy, participants undergo a carefully structured process:

• Advanced preparation for the session. In advance, set intentions for their psychedelic sessions and receive education about the psilocybin-assisted therapy.
• During the sessions. Participants attend the sessions in calming environments. The sessions can last six to eight hours. The psychedelics are administered, and participants often report that the psychedelic-induced mystical experiences are among the most meaningful and spiritually significant experiences of their lives.
• End of the session. The therapists collect vital signs throughout the psychedelic treatment sessions, and the participants undergo medical evaluations near the end of the sessions to ensure they are ready for discharge.
• Follow-up. After a psychedelic session, participants return to the therapist to discuss how to turn their experiences into durable behavioral changes. The number of additional treatments ranges from one to three over several weeks, depending on the type of mental health treatment.

With FDA approval, mental health practitioners will oversee psychedelic-assisted therapy. However, for broader medical use beyond clinical trials, additional healthcare providers may be required for the medical use of psychedelics with populations that were not involved in clinical trials.

Clinical Trials on Psychedelic Drugs and Seeking FDA Approval

No psychedelic drug is currently FDA-approved in the United States. However, a number of them are being studied in clinical trials for various mental health conditions. The use of psilocybin could gain approval within the next few years.

A few psychedelic-based medications are in the pipeline for FDA approval, including:

• Psilocybin (magic mushrooms). Naturally occurring in psilocybin mushrooms, it affects mood and perception through its actions on serotonin receptors. COMP360, HLP003 (deuterated psilocybin), and PSIL201 are all synthetic versions of psilocybin undergoing clinical trials.
• MDMA (an empathogen). Undergoing clinical trials for the treatment of severe mental health disorders, including posttraumatic stress disorder and alcohol use disorder. FDA
• Lysergic acid diethylamide (LSD). A lab-made psychedelic that influences serotonin pathways. DT120 ODT (formerly MM120), an LSD-based medicine, has received FDA “Breakthrough Therapy” designation, which accelerates a drug’s development.

As research progresses, it appears as though psychedelics are moving closer to becoming viable options for treatment for a range of mental health and pain disorders.

Legalization vs. Decriminalization of Psychedelics

Legalization makes an activity legal but regulated; decriminalization removes criminal penalties for some activities, such as possession of small amounts of substances.

Understanding the difference between legalization and decriminalization is crucial for navigating the evolving legal landscape of psychedelics.

Legalization

Legalization allows the use, sale, and possession of a substance, but it may impose some limits on those activities. For example, some types of prescription drugs are legal but can only be prescribed in limited quantities to promote safety and avoid abuse.

Legalization signifies a lawful supply, exempt from criminal prosecution and fines as long as you stay within legal limits.

Decriminalization

Often, decriminalization measures remove criminal penalties only for personal possession of small quantities of a substance. This does not eliminate criminal penalties for the sale or production of a substance, or for possession of large quantities of the substance. Decriminalization measures simply decriminalize possession.

In 2019, Denver, Colorado, became the first city in the United States to decriminalize psilocybin. Since that time, several other cities have followed suit, including Oakland and Santa Cruz, California; Washington, D.C.; and Somerville, Cambridge, and Northampton, Massachusetts.

In 2020, Oregon became the first U.S. state to both decriminalize psilocybin and legalize it for therapeutic use.

While decriminalization focuses on reducing penalties, legalization creates a lawful supply chain, ensuring safety and access for users.

State vs. Federal Regulation of Psychedelics

The regulation of psychedelics is a patchwork of state and federal laws, often creating conflicts and confusion. This debate has sparked debate among lawmakers, researchers, and the public. State and federal laws regulate the use, possession, distribution, and research of psychedelic substances.

These laws create a complex legal landscape that varies significantly across jurisdictions, presenting opportunities and challenges for medical research, access to therapies, and personal use.

Psychedelics and the Federal Controlled Substances Act

The federal government plays a significant role in regulating psychedelic substances. The Controlled Substances Act (CSA) established federal control over possession, distribution, and production of drugs.

The Drug Enforcement Agency (DEA) was then created to enforce the CSA, which classified psychedelics as Schedule I controlled substances. That meant those drugs are considered to have a high potential for abuse and no accepted medical use.

In recent years, numerous studies with psilocybin for treatment-resistant depression have supported the use of MDMA for post-traumatic stress disorder, have supported the safety and medical utility of psychedelics, and have brought about increasing acceptance and interest in the United States.

2026 Executive Order on Accelerating Medical Treatments for Serious Mental Illness

In April 2026, President Trump signed an executive order (EO) designed to advance psychedelic drugs for serious mental illness. The federal-state partnership provides:

• Funding
• Technical assistance
• Data sharing

The EO aims to accelerate access to innovative treatments for patients with serious mental illnesses. It also seeks to foster collaboration between state and federal agencies to overcome regulatory and logistical barriers.

The EO does not define what psychedelics are covered, but it does identify ibogaine as one substance that should be prioritized. Among other key provisions of the EO are the following:

• Prioritizes review of psychedelic drugs with Breakthrough Therapy designation
• Directs the FDA and the DEA to establish a Right to Try pathway for eligible patients
• Allocates at least $50 million through the Advanced Research Projects Agency for Health (ARPA-H) for federal-state collaboration
• Requires the Attorney General’s initiation of review for Schedule I drugs that have completed Phase 3 clinical trials

The EO aims to increase clinical trial participation and accelerate innovative research models that will open the door for drug approvals for psychedelic drugs.

State Laws on Psychedelics

The patchwork of state laws can create uncertainty for users and researchers. States like Oregon and Colorado have taken the lead in decriminalizing and legalizing psychedelics, while others, like New York, are considering similar measures. These state-level efforts often conflict with federal law.

State	Legal Status of Psychedelic Drugs	Legal for Sale	State Statute
Colorado	Decriminalized. Adults 21 and older can lawfully possess, grow, share, and use natural medicines.	Sales are only legal for state-licensed therapeutic centers.	Colo. Rev. Stat. § 18-18-434
Oregon	Regulated use only. Legal for supervised, therapeutic use of psilocybin at licensed centers.	Not legal.	Ore. Rev. Stat. Chapter 475A
Washington, D.C.	Deprioritized. The non-commercial cultivation, possession, distribution, and personal use of entheogenic plants and fungi are classified as lowest law enforcement priority.	Not legal.	D.C. Official Code Title 48, Chapter 9C
New Mexico	Passed legislation for medical use in 2025, with program implementation by December 31, 2027.	Program not yet implemented	New Mexico Medical Psilocybin Act

Municipality	Legal Status of Psychedelic Drugs
Seattle and King County, Washington	Lowest police priority for entheogen-related activity
San Francisco and Oakland, California	Deprioritized the use and cultivation of entheogenic plants and natural plant medicines
Detroit, Michigan	Decriminalized personal possession and therapeutic use
Minneapolis, Minnesota	Deprioritized natural, plant-based psychedelics
Cambridge and Somerville, Massachusetts	Deprioritized police enforcement for entheogens
Portland, Maine	Deprioritized police enforcement for plant-based psychedelics

Legal Implications for Users

The evolving legal landscape of psychedelics has implications for users who may find themselves facing criminal penalties for a drug violation. Psychedelic medicine is moving more into the mainstream.

• Personal use. Decriminalization reduces the risk of criminal penalties, but users should remain cautious about the enforcement of psychedelic laws.
• Medical access. Psychedelics legalization in some states offers a pathway for supervised psilocybin therapy.
• Legal risks. Users should be aware of the potential for law enforcement action, especially in jurisdictions where state and federal laws conflict.

If you have any questions about the legal landscape surrounding psychedelic laws, consult an attorney.

Get Legal Help

The legality of possession and use of psychedelic drugs remains complex, with significant divergence between drug laws at the state and federal levels. Lawmakers and public health initiatives continue to explore the potential of these medicines.

It’s critical to stay informed and seek legal guidance to understand this rapidly changing field, or to get assistance with a drug law violation charge. Consult an experienced drug and alcohol violation lawyer.